Drug Profile

A2B 530

Alternative Names: A2B-530; Autologous logic-gated Tmod™ CAR T-cell therapy - A2 Biotherapeutics; Tmod CAR T-cell Therapy - A2 Biotherapeutics

Latest Information Update: 13 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator A2 Biotherapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Colorectal cancer
New Molecular Entity No

Phase I/II Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

09 Nov 2024 Efficacy, adverse event and pharmacokinetics data from the phase I/II EVEREST-1 trial released by A2 Biotherapeutics
04 Mar 2024 A2B 530 receives Orphan Drug status for Colorectal cancer in USA
17 Nov 2021 A2 Biotherapeutics announces intention to submit IND application for Pancreatic cancer, Lung cancer and Colorectal cancer (A2 Biotherapeutics pipeline, November 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com